WITH business license and other relevant permits already obtained, Mah Sing Healthcare Sdn Bhd, Mah Sing Healthcare Sdn Bhd has practically commenced its glove manufacturing operations at its Kapar (Klang) plant.
The healthcare subsidiary of property developer Mah Sing Group Bhd expects the first shipment of its gloves to be delivered in May/June 2021.
“The group has secured sufficient raw materials to meet orders and interests from its buyers and distributors which are mainly serving markets such as the US, Canada, Middle East, Europe, UK, Japan, China, South Korea, Singapore, Russia and Latin America,” Mah Sing Healthcare pointed out.
“In addition, the company has also received the export license from the Malaysian Rubber Board which would facilitate the export business for the group’s glove manufacturing operation.”
Mah Sing Healthcare has obtained two FDA Establishment Licenses for polymer nitrile patient examination glove and latex patient examination glove from the US Food & Drug Administration (FDA) which all glove manufacturers are required to register in order to sell gloves in the US.
It is also progressing well in obtaining FDA 510(k) Premarket Notification and the Conformitè Europëenne (CE) Marking for export to the US and European markets respectively.
This new milestone places Mah Sing among the first few new glove entrants in Malaysia to commence glove production to meet immediate market demand.
“The rapid progress of Mah Sing’s glove venture is typical of the property developer which is known for its quick turnaround business model,” the company said.
Execution of the glove venture is on schedule as there will be six production lines on track to be operational in 2Q 2021 followed by another six production lines in 3Q 2021.
The maximum production capacity of 12 lines is up to 3.68 billion pieces of gloves per annum. These 12 units of new, high speed glove dipping machines – producing at a speed of 38,000 pieces of gloves per production line per hour – come under Phase 1 of Mah Sing’s glove manufacturing business.
Structural increase in glove usage because of new norms, fears of re-infection, higher health awareness, as well as hygiene compliance requirements for healthcare and non-healthcare sectors will continue to support strong demand for the gloves post-pandemic.
At 10.41am, Mah Sing was up 0.5 sen or 0.55% to 91.5 sen with 1.12 million shares traded, thus valuing the company at RM2.22 bil. – May 24, 2021
